Cyclerion Therapeutics, Inc. Gains 73.18%
Cyclerion Therapeutics, Inc. (CYCN:NASDAQ) shot up at $3.81, representing a gain of 73.2%. On Wed, Jul 10, 2024, CYCN:NASDAQ hit a New 2-Week High of $3.81. From Wed, Jun 26, 2024, the stock recorded 55.56% Up Days and 70.00% Green Days
About Cyclerion Therapeutics, Inc. (CYCN:NASDAQ)
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases.Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators.
Top 10 Gainers:
- Kazia Therapeutics Limited (KZIA:NASDAQ), 248.02%
- Inspire Veterinary Partners Inc. (IVP:NASDAQ), 110.23%
- Cingulate Inc. (CING:NASDAQ), 74.05%
- Cyclerion Therapeutics, Inc. (CYCN:NASDAQ), 73.18%
- Ampco-Pittsburgh Corporation (AP:NYSE), 60.81%
- Longeveron Inc. (LGVN:NASDAQ), 58.54%
- uniQure N.V. (QURE:NASDAQ), 51.72%
- Antelope Enterprise Holdings Limited (AEHL:NASDAQ), 50.83%
- Phoenix New Media Limited (FENG:NYSE), 49.26%
- Virpax Pharmaceuticals Inc. (VRPX:NASDAQ), 46.55%